RxDoctor Payments DataLook up a doctor →

John Vanchiere

Pediatric Infectious Diseases · Shreveport, LANPI 1871673111

Payments from drug & device makers

$7,027,718in general payments, 2019–2025

Across 464 payments — averaging $15,146 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6.7M
  • Merck$107K
  • Tetraphase Pharmaceuticals, Inc.$49K
  • Hoffmann-la Roche Limited$33K
  • Biocryst Pharmaceuticals, Inc.$30K
  • Genentech, Inc.$19K
  • plus $43K from 9 others
$1,825in research payments, 2019–2025

Across 2 payments — averaging $912.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biocryst Pharmaceuticals, Inc.$2K

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few pediatric infectious diseases providers in Louisianato place this figure against a meaningful peer group, so we don't.

Other pediatric infectious diseases in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →